GLP-1 Effects on Islets: Hormonal, Neuronal, Or Paracrine?
Total Page:16
File Type:pdf, Size:1020Kb
DIABETES PATHOPHYSIOLOGY GLP-1 Effects on Islets: Hormonal, Neuronal, or Paracrine? 1 MARC Y. DONATH, MD control of glycemia through the activation 2 RÉMY BURCELIN, PHD of the gut brain axis. Furthermore, the di- rect administration of the DPP-4 inhibitor into the rat portal vein significantly in- creased portal (but not peripheral) GLP-1 ccording to the classical incretin con- (5) within minutes from the absorption and insulin levels and decreased glucose Acept, glucagon-like peptide (GLP)-1 of glucose and lipids. The final aim of concentrations (14). However, despite the is viewed as a hormone produced this axis is to anticipate the breakthrough large amount of experimental evidence de- in the intestinal L cells and acting via of the nutrients into the blood and their scribed above showing the important role the circulation on satiety in the brain, better handling. Indeed, GLP-1 secreted of GLP-1 on the gut-to-brain axis, a recent gut motility, and insulin and glucagon from L cells can influence brain neuronal observation in mice suggests that the circu- secretion in the pancreatic islet. How- activities via an alternative neural path- lating GLP-1 could also directly access the ever, in contrast to typical hormones, way initiated by sensors in the hepatic brain and the b-cells and induce insulin plasma levels of GLP-1 are relatively low portal region (6–8). Thereby, the vagus secretion (15). Transgenic mice that ex- with a very short half-life. Furthermore, nerve transmits the metabolic infor- pressed the human GLP-1 receptor in islets GLP-1 is rapidly inactivated by dipep- mation to the nucleus tractus solitarii and in pancreatic ductal cells within the tidyl peptidase-4 (DPP-4) in the vicinity in the brain stem, which relays the glu- background of the GLP-1 receptor knock- of L cells within ,1 min from the secre- cose signal to hypothalamic nuclei (9). out mice were characterized by increased tion of the gut peptide (1,2). This rapid This process is called the gut-to-brain- glucose-induced insulin secretion that was metabolism of GLP-1 raises questions to-periphery axis. Seminal studies from sufficient to normalize glucose tolerance, about how its effects are mediated on our group showed that the direct infusion whereas no effect on food intake, hindbrain target organs such as pancreatic b-cells. of glucose into the portal vein of mice at a c-fos expression, or gastric emptying was In this review, we will discuss possible low rate increased muscle glucose utiliza- observed (15). This new set of data suggests alternative pathways for the incretin ef- tion through an insulin-independent that part of the gut-released GLP-1 may re- fect on pancreatic islet. These involve mechanism (10–12). This process re- semble some of the incretin effect through a Lcell–derived GLP-1 via neuronal acti- quired the activation of the hepatoportal process not involving the gut-brain axis. vation and a-cell–derived GLP-1 via vein glucose sensor (6). The blockage of Alternatively or additionally, the release of auto/paracrine effects. Of note, GLP-1 is the portal GLP-1 receptor by exendin 9 GLP-1 from an intraislet processing may not acting alone, and its effect can be directly into the hepatoportal vein or in contribute to triggering glucose-induced modulated by other factors including GLP-1 receptor knockout mice (8) pre- insulin secretion (see below). GIP.Sincenodataareavailableyetin vented the portal glucose sensor activa- A further demonstration of the role the present context, we have limited this tion for the control of muscle glucose played by the GLP-1–dependent gut- review to GLP-1. utilization (8) or insulin secretion (8,13). brain axis is the recent analysis of the ther- Furthermore, the inhibition of the enteric apeutic role of GLP-1 receptor agonists on GLP-1 in the gut-to-brain-to- DPP-4 by small doses of DPP-4 inhibitor neuropathy in mice with diabetes owing periphery axis for the control of improved glucose tolerance without in- to streptozotocin (16). The authors glucose metabolism creasing the blood concentration of GLP-1 – showed the presence of the GLP-1 recep- Recent rodent data show that GLP-1 can through a GLP-1 receptor dependent tor on the lumbar dorsal root ganglion by induce its metabolic actions by interact- manner (3). In such conditions, the vagus immunohistochemical analyses and ing with its receptors in extrapancreatic nerve activity was increased in response to further demonstrated that exendin-4 in- locations such as the gut to activate the oral DPP-4 inhibitors, whereas the intrave- creases the neurite outgrowth. Importantly, submucosal and the myenteric nervous nous administration of the drug had no the delayed current perception threshold plexi (3,4) and the brain, which then therapeutic effect, further suggesting the and motor and sensory nerve conduction transmit the signal to peripheral tissues important role of enteric GLP-1 on the velocity impaired by type 1 diabetes, was ccccccccccccccccccccccccccccccccccccccccccccccccc improved by the GLP-1 agonist (16). From the 1Clinic of Endocrinology, Diabetes & Metabolism, University Hospital Basel, Basel, Switzerland; and Hence, gut-released hormone would fur- 2INSERM U1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France. ther favor the gut-brain axis by control- Corresponding author: Marc Y. Donath, [email protected]. ling the enteric neural development. This publication is based on the presentations from the 4th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy). The Congress and the publication of this supplement were Similarly, a therapeutic role of the gut- made possible in part by unrestricted educational grants from Abbott, AstraZeneca, Boehringer Ingelheim, brain axis has been proposed regarding Bristol-Myers Squibb, Eli Lilly, Ethicon Endo-Surgery, Janssen, Medtronic, Novo Nordisk, Sanofi, and the therapeutic efficacy of gastric bypass. Takeda. Obese and diabetic patients who under- DOI: 10.2337/dcS13-2015 © 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly went this type of bariatric surgery lose cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/ weight within months and reverse their licenses/by-nc-nd/3.0/ for details. diabetes status within weeks from the care.diabetesjournals.org DIABETES CARE, VOLUME 36, SUPPLEMENT 2, AUGUST 2013 S145 GLP-1 effects on islets surgery. It has been proposed that a hor- The next step was to uncover the and obesity are characterized by an acti- monal characteristic is that these patients molecular trigger of PC1/3 with subse- vation of the innate immune system secrete large amounts of GLP-1 (17) that quent GLP-1 production in a-cells. Two reflected by an increase in various in- could even lead to uncontrolled insulin important studies point to a direct effect flammatory markers including elevated secretion and hypoglycemic episodes of elevated glucose concentrations. Thus, plasma levels of IL-6 (33). It was shown in (18), although this still needs to be con- in the Psammomy obesus, high-energy diet mice that elevated IL-6 levels in response firmed. However, numerous other pepti- induces diabetes along with a significant to exercise (34), as well as acute and des such as peptide YY, oxyntomodulin, increase of GLP-1 in the portal vein and chronic IL-6 administration in mice, can and GLP-2 may be responsible for the ac- pancreas extract (31). Isolated islets from stimulate GLP-1 secretion from intestinal tivation of the gut-brain axis in patients hyperglycemic animals released more L cells and pancreatic a-cells leading to with bypass surgery (19). GLP-1 than in controls. This ex vivo effect improved glucose homeostasis (35). In vi- Altogether, the role of GLP-1 on the was confirmed in vitro by culture of nor- tro, IL-6 increased GLP-1 synthesis and gut-to-brain-to-periphery axis is now mal P. obesus islets with high glucose, secretion from entero-endocrine L cells considered a major mechanism of action which induced GLP-1 release. Similarly, both acutely and chronically. IL-6 also in- of the gut hormone for the control of high glucose concentrations increased creased GLP-1 synthesis and secretion glycemia. Many controversial debates are PC1/3 in rat islets, while in an a-cell line from human pancreatic a-cells in asso- ongoing regarding its role in the control of glucose increased GLP-1 and decreased ciation with increased proglucagon food intake. Similarly, the production of glucagon secretion (32). and PC1/3 transcription. Similarly, the GLP-1 into the brain and the colocalized An additional trigger of GLP-1 is beneficial effects of elevated IL-6 were receptors have also been important fields interleukin (IL)-6. Indeed, type 2 diabetes showninanimalmodelsoftype2 of investigation in explaining the meta- bolic effect of this insulinotropic peptide. a-Cell as a source of GLP-1 GLP-1 is spliced from its precursor pro- glucagon in intestinal L cells through processing by the enzyme PC1/3 (20– 23). In the pancreatic a-cell, proglucagon is processed by PC2 to yield glucagon (24,25). Adult a-cells are thought to pro- duce little GLP-1. However, a switch of PC2 to PC1/3 is sufficient to convert the a-cell from a hyperglycemia-promoting cell to one that lowers blood glucose lev- els and promotes islet survival (26). Fur- thermore, several animal studies show that islet-derived GLP-1 may be stimu- lated by increased demand of insulin se- cretion, suggesting that locally produced GLP-1 may play a role in the long-term b-cell adaptation. Indeed, b-cell destruc- tion with streptozotocin leads to hyper- glycemia followed by b-cell regeneration associated with a-cell hyperplasia and pancreatic PC1/3 upregulation along with increased pancreatic and circulating levels of GLP-1 and GLP-1–to–glucagon ratio (27,28).